Organogenesis (ORGO) said late Monday that it plans to file a Biologics Licenses Application for ReNu, its amniotic suspension allograft developed to manage symptomatic knee osteoarthritis, by the end of the year.
The company said the move followed "the successful" completion of a planned Type-B meeting with the US Food and Drug Administration.
Shares of the company were up 9% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments